CCCC · Insider Trading
C4 Therapeutics, Inc.
Every open-market purchase and sale reported by CCCC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Donna Roy Grogan | Director | A | +4,618 | +$14.50K |
| 2026-10-02 | Kenneth Carl Anderson | Director | A | +3,662 | +$11.50K |
| 2026-09-21 | Kendra Adams | Chief Financial Officer | MIXED | +3,475 | −$9.41K |
| 2026-07-13 | Leonard Reyno | Chief Medical Officer | MIXED | +7,928 | −$30.03K |
| 2026-07-02 | Donna Roy Grogan | Director | A | +3,341 | +$14.50K |
| 2026-07-02 | Kenneth Carl Anderson | Director | A | +2,650 | +$11.50K |
| 2026-06-26 | Ronald Harold Wilfred Cooper | Director | A | +62,000 deriv. | — |
| 2026-06-26 | Donna Roy Grogan | Director | A | +62,000 deriv. | — |
| 2026-06-26 | Utpal Koppikar | Director | A | +62,000 deriv. | — |
| 2026-06-26 | Laura Bessen | Director | A | +62,000 deriv. | — |
| 2026-06-26 | Owen Hughes | Director | A | +62,000 deriv. | — |
| 2026-06-26 | Stephen Fawell | Director | A | +62,000 deriv. | — |
| 2026-06-26 | Kenneth Carl Anderson | Director | A | +62,000 deriv. | — |
| 2026-06-26 | Steven L. Hoerter | Director | A | +62,000 deriv. | — |
| 2026-06-04 | Kenneth Carl Anderson | Director | M | +1,070 | +$2.26K |
| 2026-04-03 | Donna Roy Grogan | Director | A | +5,370 | +$14.50K |
| 2026-04-03 | Kenneth Carl Anderson | Director | A | +4,259 | +$11.50K |
| 2026-02-18 | Leonard Reyno | Chief Medical Officer | MIXED | +254,371 | −$31.33K |
| 2026-02-18 | Mark Mossler | Chief Accounting Officer | MIXED | +63,132 | −$6.18K |
| 2026-02-18 | Kelly Schick | Chief People Officer | MIXED | +216,946 | −$17.02K |
| 2026-02-18 | Andrew Hirsch | President & CEO | MIXED | +753,914 | −$91.12K |
| 2026-02-18 | Kendra Adams | Chief Financial Officer | MIXED | +257,456 | −$32.59K |
| 2026-02-18 | Scott N Boyle | Chief Business Officer | MIXED | +216,946 | −$17.02K |
| 2026-02-18 | Paige Mahaney | Chief Scientific Officer | MIXED | +244,604 | −$4.62K |
| 2026-01-16 | Leonard Reyno | Chief Medical Officer | Sell | −10,000 | −$22.20K |
| 2026-01-05 | Donna Roy Grogan | Director | A | +7,513 | +$14.50K |
| 2026-01-05 | Kenneth Carl Anderson | Director | A | +5,958 | +$11.50K |
| 2025-10-30 | Paige Mahaney | Chief Scientific Officer | MIXED | +13,556 | −$14.56K |
| 2025-10-03 | Donna Roy Grogan | Director | A | +6,740 | +$14.49K |
| 2025-10-03 | Kenneth Carl Anderson | Director | A | +5,349 | +$11.50K |
| 2025-09-19 | Kendra Adams | Chief Financial Officer | MIXED | +3,475 | −$9.21K |
| 2025-07-15 | Leonard Reyno | Chief Medical Officer | MIXED | +7,943 | −$14.69K |
| 2025-07-14 | Leonard Reyno | Chief Medical Officer | F | −7,382 | −$14.69K |
| 2025-07-02 | Donna Roy Grogan | Director | A | +9,609 | +$14.51K |
| 2025-07-02 | Kenneth Carl Anderson | Director | A | +7,616 | +$11.50K |
| 2025-06-20 | Donna Roy Grogan | Director | A | +35,500 deriv. | — |
| 2025-06-20 | Utpal Koppikar | Director | A | +35,500 deriv. | — |
| 2025-06-20 | Ronald Harold Wilfred Cooper | Director | A | +35,500 deriv. | — |
| 2025-06-20 | Laura Bessen | Director | A | +35,500 deriv. | — |
| 2025-06-20 | Kenneth Carl Anderson | Director | A | +35,500 deriv. | — |
| 2025-06-20 | Steven L. Hoerter | Director | A | +35,500 deriv. | — |
| 2025-06-20 | Owen Hughes | Director | A | +35,500 deriv. | — |
| 2025-06-20 | Stephen Fawell | Director | A | +35,500 deriv. | — |
| 2025-04-03 | Donna Roy Grogan | Director | A | +9,581 | +$13.75K |
| 2025-04-03 | Kenneth Carl Anderson | Director | A | +7,841 | +$11.25K |
| 2025-02-18 | Mark Mossler | Chief Accounting Officer | F | −1,586 | −$5.04K |
| 2025-02-18 | Andrew Hirsch | President & CEO | MIXED | +201,283 | −$70.65K |
| 2025-02-18 | Leonard Reyno | Chief Medical Officer | MIXED | +81,955 | −$16.36K |
| 2025-02-18 | Jolie Siegel | Chief Legal Officer | MIXED | +51,451 | −$16.10K |
| 2025-02-18 | Kendra Adams | Chief Financial Officer | MIXED | +80,678 | −$20.46K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Andrew Hirsch | President & CEO | 1,123,145 | $3.56M |
| Kendra Adams | Chief Financial Officer | 382,323 | $1.21M |
| Leonard Reyno | Chief Medical Officer | 379,803 | $1.20M |
| Paige Mahaney | Chief Scientific Officer | 336,910 | $1.07M |
| Kelly Schick | Chief People Officer | 308,885 | $979.17K |
| Scott N Boyle | Chief Business Officer | 306,070 | $970.24K |
| Kenneth Carl Anderson | Director | 205,489 | $651.40K |
| Donna Roy Grogan | Director | 79,471 | $251.92K |
| Mark Mossler | Chief Accounting Officer | 75,184 | $238.33K |
| Jolie Siegel | Chief Legal Officer | 54,353 | $172.30K |
| Utpal Koppikar | Director | 5,667 | $17.96K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CCCC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.